Thrombocytopenia—Platelet Support or Growth Factors?

References

• Keleman, E., Cserhati, I. and Tanos, B. (1958). Demonstration and some properties of human thrombopoietin in thrombocythaemic sera. Acta Haematol., 20, 350–355.
   PubMedGoogle Scholar
• Duke, W. W. (1910). The relation of blood platelets to hemorrhagic disease. Description of a method for determining the bleeding time and coagulation time and report of 3 cases of hemorrhagic disease relieved by transfusion. JAMA, 55, 1185–1192.
   Google Scholar
• Hersh, E. M., Bodey, G. P., Boyd, A. N. and Freireich, E. J. (1965). Causes of death in acute leukaemia: a ten year study of 414 patients from 1954–1963. JAMA, 193, 99–103.
   PubMed Web of Science ®Google Scholar
• Han, T., Stutzman, L., Cohen, E. and Kim, U. (1966). Effect of platelet transfusion on haemorrhage in patients with acute leukaemia. Cancer, 19, 1937–1942.
   PubMed Web of Science ®Google Scholar
• The Trial to Reduce Alloimmunization to Platelets Study Group. (1997). Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. New Engl. J. Med., 337, 1861–1869.
   PubMed Web of Science ®Google Scholar
• Slichter, S. (1980). Controversies in platelet transfusion therapy. Annu. Rev. Med., 31, 509–540.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health Consensus Conference. (1987). Platelet transfusion therapy. JAMA, 257, 1777–1780.
   PubMed Web of Science ®Google Scholar
• British Committee for Standards in Haematology. (1992). Guidelines for platelet transfusions. Transfus. Med., 2, 311–318.
   PubMed Web of Science ®Google Scholar
• Contreras, M. (1998). Consensus Conference on Platelet Transfusion. Final statement. Br. J. Haematol., 101, 614–615.
   Google Scholar
• Slichter, S. J. (1990). Platelet transfusion therapy. Haematology/Oncology Clinics of North America, 4, 291–311.
   PubMed Web of Science ®Google Scholar
• Surgenor, D. M., Wallace, E. L., Hao, S. H. and Chapman, R. H. (1989). Collection and transfusion of blood in the United States, 1982–1988. N. Engl. J. Med., 322, 1646–1651.
   Web of Science ®Google Scholar
• Wallace, E. L., Churchill, W. H., Surgenor, D. M. et al. (1995). Collection and transfusion of blood and blood components in the United States, 1992. Transfusion, 35, 802–812.
   PubMed Web of Science ®Google Scholar
• Beutler, E. (1993). Platelet transfusions: the 20,000/uL trigger. Blood, 81, 1411–1413.
   PubMed Web of Science ®Google Scholar
• Wallace, E. L., Churchill, W. H., Surgenor, D. M., Cho, G. S. and McGurk, S. (1998). Collection and transfusion of blood and blood components in the United States, 1994. Transfusion, 38, 625–636.
   PubMed Web of Science ®Google Scholar
• Slichter, S. J. and Harker, L. A. (1978). Thrombocytopenia: Mechanisms and management of defects in platelet production. Clin. Haematol., 7, 523–539.
   PubMedGoogle Scholar
• Schiffer, C. A. (1992). Prophylactic platelet transfusion. Transfusion, 32, 295–298.
   PubMed Web of Science ®Google Scholar
• Gmur, J., Burger, J., Schanz, U., Fehr, J. and Schaffner, A. (1991). Safety of stringent prophylactic platelet transfusion policy for patients with acute leukaemia. Lancet, 338, 1223–1226.
   PubMed Web of Science ®Google Scholar
• Pisciotto, P. T., Benson, K., Hume, H. et al. (1995). Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients. Transfusion, 35, 498–502.
   PubMed Web of Science ®Google Scholar
• Kretschmer, V. (1995). Platelet transfusions in Europe—analysis of the ESFH questionnaire. Infusiontherapie und Transfusionsmedizin, 22 (suppl. 2), 55.
   Google Scholar
• Murphy, M. F., Murphy, W., Wheatley, K. and Goldstone, A. H. (1998). Survey of use of platelet transfusions in centres participating in MRC leukaemia trials. Br. J. Haematol., 102, 875–876.
   PubMed Web of Science ®Google Scholar
• Wandt, H., Frank, M., Schneider, C. et al. (1998). Safety and cost effectiveness of a 10 × 109/L compared with the traditional 20 × 109/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukaemia. Blood, 91, 3601–3606.
   PubMed Web of Science ®Google Scholar
• Rebulla, P., Finazzi, G., Marangoni, F. et al. (1997). The threshold for prophylactic platelet transfusions in adults with acute myeloblastic leukaemia. N. Engl. J. Med., 337, 1870–1875.
   PubMed Web of Science ®Google Scholar
• Springer, W. and von Ruecker, A. (1998). Difficulties in determining prophylactic transfusion thresholds of platelets in leukaemia patients. Blood, 92, 2183–2184.
   PubMed Web of Science ®Google Scholar
• Kickler, T., Rothe, M., Blosser, L., Schisano, T. and van Hove, L. (1998). Improved platelet transfusion decisions using the Immunoplttm method on the Cell-Dyn 4000. Br. J. Haematol., 102, 214.
   Web of Science ®Google Scholar
• Souyri, M., Vigon, I., Penciolelli, J.-F., Heard, J.-M., Tambourin, P. and Wendling, F. (1990). A putative truncated cytokine receptor gene transduced by the myeloproliferative leukaemia virus immortalizes hematopoietic progenitors. Cell, 63, 1137–1147.
   PubMed Web of Science ®Google Scholar
• Vigon, I., Momon, J.-P., Cocault, L. et al. (1992). Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc. Natl. Acad. Sci. USA, 89, 5640–5644.
   PubMed Web of Science ®Google Scholar
• de Sauvage, F. J., Hass, P. E., Spencer, S. D. et al. (1994). Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-mpl ligand. Nature, 369, 533–538.
   PubMed Web of Science ®Google Scholar
• Bartley, T. D., Bogenberger, J., Hunt, P. et al. (1994). Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell, 77, 1117–1124.
   PubMed Web of Science ®Google Scholar
• Lok, S., Kaushansky, K., Holly, R. D. et al. (1994). Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature, 369, 565–568.
   PubMed Web of Science ®Google Scholar
• Sohma, Y., Akahori, H., Seki, N. et al. (1994). Molecular cloning and chromosomal localization of the human thrombopoietin gene. FEBS Letters, 353, 57–61.
   PubMed Web of Science ®Google Scholar
• Hokom, M. M., Lacey, D., Kinstler, O. B. et al. (1995). Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice. Blood, 86, 4486–4492.
   PubMed Web of Science ®Google Scholar
• Kaushansky, K. (1998). Thrombopoietin. New Engl. J. Med., 339, 746–754.
   PubMed Web of Science ®Google Scholar
• Broudy, V. C., Lin, N. L. and Kaushansky, K. (1995). Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood, 85, 1719–1726.
   PubMed Web of Science ®Google Scholar
• Kaushansky, K. (1998). Thrombopoietin and the hematopoietic stem cell. Blood, 92, 1–3.
   PubMed Web of Science ®Google Scholar
• Harker, L. A., Marzec, U. M., Hunt, P. et al. (1996). Dose response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Blood, 88, 511–521.
   PubMed Web of Science ®Google Scholar
• Kaushansky, K., Lin, N., Grossmann, A., Hames, J., Spragel, K. H., and Broudy, V. C. (1995). Thrombopoietin expands erythroid progenitors, increases red cell production, and enhances erythroid recovery after myelosuppressive therapy. J. Clin. Invest, 96, 1683–1687.
   PubMed Web of Science ®Google Scholar
• Alexander, W. S., Roberts, A. W., Nicola, N. A., Li., R. and Metcalf, D. (1996). Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietin receptor c-Mpl. Blood, 87, 2162–2170.
   PubMed Web of Science ®Google Scholar
• Chen, J., Herceg-Harjacek, H. I., Groopman., J. E. and Grabarek, J. (1995). Regulation of platelet activation in vitro by the c-Mpl ligand, thrombopoietin. Blood, 86, 4054–4062.
   PubMed Web of Science ®Google Scholar
• Nichol, J. L., Hokom, M. M., Homkohl, A. et al. (1995). Megakaryocyte growth and development factor: analysis of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia. J. Clin. Invest, 95, 2973–2978.
   PubMed Web of Science ®Google Scholar
• Kuter, D. J. and Rosenberg, R. D. (1995). The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulphan-induced thrombocytopenia in the rabbit. Blood, 85, 2720–2730.
   PubMed Web of Science ®Google Scholar
• Sungaran, R., Markovic, B. and Chong, B. H. (1997). Localization and regulation of thrombopoietin mRNA expression in human kidney, liver, bone marrow and spleen using in situ hybridization. Blood, 89, 101–107.
   PubMed Web of Science ®Google Scholar
• Stoffel, R., Wiestner, A. and Skoda, R. C. (1996). Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood, 87, 567–573.
   PubMed Web of Science ®Google Scholar
• Nagata, Y., Shozaki, Y., Nagahisa, H. et al. (1997). Serum thrombopoietin level is not regulated by transcription but by the total counts of both megakaryocytes and platelets during thrombocytopenia and thrombocytosis. Thrombosis and Haemostasis, 77, 808–814.
   PubMed Web of Science ®Google Scholar
• Hou, M., Andersson, P. O., Stockelberg, D., Mellqvist, U. H., Ridell, B. and Wadenvik, H. (1998). Plasma thrombopoietin levels in thrombocytopenic states: implication for a regulatory role of bone marrow megakaryocytes. Br. J. Haematol, 101, 420–424.
   PubMed Web of Science ®Google Scholar
• Meng, Y. G., Martin, T. G., Peterson, M. L., Shuman, M. A., Cohen, R. L. and Wong, W. L. (1996). Circulating thrombopoietin levels in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation. Br. J. Haematol., 95, 535–541.
   PubMed Web of Science ®Google Scholar
• Marsh, J. C. W., Gibson, F. M., Prue, R. L. et al. (1996). Serum thrombopoietin levels in patients with aplastic anaemia. Br. J. Haematol., 95, 605–610.
   PubMed Web of Science ®Google Scholar
• Schrezenmeier, H., Greisshammer, M., Hornkohl, A. et al. (1998). Thrombopoietin serum levels in patients with aplastic anaemia: correlation with platelet count and persistent elevation in remission. Br. J. Haematol., 100, 571–576.
   PubMed Web of Science ®Google Scholar
• Nagasawa, T., Hasegawa, Y., Shimizu, S. et al. (1998). Serum thrombopoietin level is mainly regulated by megakaryocyte mass rather than platelet mass in human subjects. Br. J. Haematol., 101, 242–244.
   PubMed Web of Science ®Google Scholar
• Kosugi, S., Kurata, Y., Tomiyama, Y. et al. (1996). Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br. J. Haematol., 93, 704–706.
   PubMed Web of Science ®Google Scholar
• Farese, A., Hunt, P., Boone, T. and MacVittie, T. J. (1995). Recombinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal nonhuman primates. Blood, 86, 54–59.
   PubMed Web of Science ®Google Scholar
• Ulich, T. R., del Castillo, J., Yin, S. et al. (1995). Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice. Blood, 86, 971–976.
   PubMed Web of Science ®Google Scholar
• Akahori, H., Shibuya, K., Obuchi, M. et al. (1996). Effect of recombinant human thrombopoietin in nonhuman primates with chemotherapy-induced thrombocytopenia. Br. J. Haematol., 94, 722–728.
   PubMed Web of Science ®Google Scholar
• Neelis, K., Dubbelman, Y. D., Qingliang, L. et al. (1997). Simultaneous administration of TPO and G-CSF after cytoreductive treatment of rhesus monkeys prevents thrombocytopenia, accelerates platelet and red cell reconstitution, alleviates neutropenia, and promotes the recovery of immature bone marrow cells. Exp. Hematol, 25, 1084–1093.
   PubMed Web of Science ®Google Scholar
• Van de Ven, C., Fernandez, G. W., Herbst, T. et al. (1998). The haemopoietic effects of thrombopoietin administered post myelosuppressive carboplatin therapy compared to either pre- and post- or prechemotherapy. Br. J. Haematol., 102, 775–782.
   PubMed Web of Science ®Google Scholar
• Shibuya, K., Akahori, H., Takahashi, K. et al. (1998). Multilineage hematopoietic recovery by a single injection of pegylated recombinant human megakaryocyte growth and development factor in myelosuppressed mice. Blood, 91, 37–45.
   PubMed Web of Science ®Google Scholar
• Fibbe, W. E., Heemskerk, D. P. M., Laterveer, L. et al. (1995). Accelerated reconsititution of platelets and erythrocytes after syngeneic transplantation of bone marrow cells derived from thrombopoetin pretreated donor mice. Blood, 86, 3308–3313.
   PubMed Web of Science ®Google Scholar
• Molineux, G., Hartley, C., McElroy, P. et al. (1996). Megakaryocyte growth and development factor accelerates platelet recovery in peripheral blood progenitor cell transplant recipients. Blood, 88, 366–376.
   PubMed Web of Science ®Google Scholar
• Basser, R. L., Rasko, J. E. J., Clarke, K. et al. (1996). Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet, 348, 1279–81.
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj, S., Murray, L. J., Bueso-Ramos, C. et al. (1997). Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann. Intern. Med., 126, 673–681.
   PubMed Web of Science ®Google Scholar
• Fanucchi, M., Glaspy, J., Crawford, J. et al. (1997). Effects of polyethylene glycol conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N. Engl. J. Med., 336, 404–409.
   PubMed Web of Science ®Google Scholar
• Basser, R. L., Rasko, J. E. J., Clarke, K. et al. (1997). Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood, 89, 3118–3128.
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj, S., Verschraegen, C., McGarry, L. et al. (1997). Recombinant human thrombopoietin attenuates high-dose carboplatin-induced thrombocytopenia in patients with gynecologic malignancy. Blood, 90, (suppl. 1), 580a.
   Google Scholar
• Archimbaud, E., Ottmann, O., Liu Yin, J. A. et al. (1996). A randomised, double-blind, placebo-controlled study using PEG-rHuMGDF as an adjunct to chemotherapy for adults with de novo acute myeloid leukaemia: early results. Blood, 88, (suppl. 1), 447a.
   Google Scholar
• Schiffer, C. A., Miller, K., Larson, R. A. et al. (1998). A double blind, placebo controlled trial evaluating pegylated recombinant megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy in patients with acute myeloid leukaemia. Blood, 92, (suppl. 1), 313a.
   Google Scholar
• Geissler, K., Kabrna, E., Stengg, S. et al. (1998). Recombinant human megakaryocyte growth and development factor increases levels of circulating haemopoietic progenitor cells post chemotherapy in patients with acute myeloid leukaemia. Br. J. Haematol., 102, 535–543.
   PubMed Web of Science ®Google Scholar
• Rasko, J. E. J., Basser, R. L., Boyd, J. et al. (1997). Multilineage mobilization of peripheral blood progenitor cells in humans following administration of PEG-rHuMGDF. Br. J. Haematol., 97, 871–880.
   PubMed Web of Science ®Google Scholar
• Beveridge, R., Schuster, M., Waller, E. et al. (1997). Randomized, double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor in breast cancer patients following autologous bone marrow transplantation. Blood, 90, (suppl. 1), 580a.
   Google Scholar
• Glaspy, J., Vredenburgh, J., Demetri, G. D. et al. (1997). Effects of pegylated recombinant human megakaryocyte growth and development factor before high dose chemotherapy with peripheral blood progenitor cell support. Blood, 90 (suppl. 1), 580a.
   Google Scholar
• Bolwell, B., Vredenburgh, J., Overmoyer, B. et al. (1997). Safety and biologic effect of pegylated recombinant human megakaryocyte growth and development factor in breast cancer patients following autologous peripheral blood progenitor cell transplantation. Blood, 90 (suppl. 1), 171a.
   Google Scholar
• Nash, R., Kurzrock, R., DiPersio, J. et al. (1997). Safety and activity of recombinant human thrombopoietin in patients with delayed platelet recovery. Blood, 90 (suppl. 1), 262a.
   Google Scholar
• Kuter, D., McCullough, J., Romo, J. et al. (1997). Treatment of platelet donors with pegylated recombinant human megakaryocyte growth and development factor increases circulating platelet counts and platelet apheresis yields and increases platelet increments in recipients of platelet transfusions. Blood, 90 (suppl. 1), 579a.
   Google Scholar
• Du, X. and Williams, D. A. (1997). Interleukin-11: review of molecular, cell biology, and clinical use. Blood, 89, 3897–3908.
   PubMed Web of Science ®Google Scholar
• Tepler, I., Elias, L., Smith, J. W. II et al. (1996). A randomized placebo-controlled trial of recombinant interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood, 87, 3607–3614.
   PubMed Web of Science ®Google Scholar
• Cwirla, S. E., Balasubramanian, P., Duffin, D. J. et al. (1997). Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science, 276, 1696–1699.
   PubMed Web of Science ®Google Scholar
• Deng, B., Banu, N., Malloy, B. et al. (1998). An agonist murine monoclonal antibody to the human c-mpl receptor stimulates megakaryocytopoiesis. Blood, 92, 1981–1988.
   PubMed Web of Science ®Google Scholar
• Goodnough, L. T., Kolodziej, M., Ehlenbeck, C. et al. (1995). A phase 1 study of safety and efficacy for infusible platelet membrane in patients. Blood, 86(suppl. 1), 610a.
   Google Scholar
• Yen, R. K. C., Ho, T. W. C. and Blajchman, M. A. (1995). A new hemostatic agent: Thrombospheres shorten the bleeding time in thrombocytopenic rabbits. Thrombosis and Haemostasis, 73, 986.
   Web of Science ®Google Scholar
• Levi, M., Friederich, P. W., Middleton, S. et al. (1999). Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits. Nature Medicine, 5, 107–111.
   PubMed Web of Science ®Google Scholar
• Read, M. S., Reddick, R. L., Bode, A. P. et al. (1995). Preservation of hemostatic and structural properties of rehydrated lyophilized plateletsl: potential for longterm storage of dried platelets for transfusion. Proceedings of the National Academy of Science, 92, 397–401.
   PubMed Web of Science ®Google Scholar
• Bode, A. P., Read, M. S. and Lust, R. M. (1994). Hemostatic properties of lyophilized platelets in tests of bleeding times. Transfusion, 34 (10S), S307.
   Google Scholar
• Nevo, S., Swan, V., Enger, C. et al. (1998). Acute bleeding after bone marrow transplantation—incidence and effect on survival. A quantitative analysis in 1,402 patients. Blood, 91, 1469–1477.
   PubMed Web of Science ®Google Scholar
• Norol, F., Bierling, P., Roudot-Thoraval, F. et al. (1998). Platelet transfusion: a dose response study. Blood, 92, 1448–1453.
   PubMed Web of Science ®Google Scholar
• Yagi, M., Ritchie, K. A., Sitnicka, E. et al. (1998). Sustained substantial ex vivo production of hematopietic stem cells mediated by thrombopoietin. Blood, 92 (suppl. 1), 504a.
   Google Scholar
• Goltry, K. L., Manchel, I., Robertson, W. M. and Smith, A. K. (1998). Increased expansion of primitive hematopoietic cells in unselected cord blood cultures using combinations of stem cell factor, thrombopoietin, and FLT-3 ligand. Blood, 92 (suppl. 1), 645a.
   Google Scholar
• Van den Oudenrijn, S., de Haas, M., van der Schoot, E. et al. (1998). Megakaryocyte development from bone marrow, cord blood or peripheral blood-derived progenitor cells. Transfus. Med., 8, 246.
   Google Scholar